Top

Published in:

01-05-2024 | Diabetes | Research

Linarin Ameliorates Restenosis After Vascular Injury in Type 2 Diabetes Mellitus via Regulating ADAM10-Mediated Notch Signaling Pathway

Authors: Aihua Jiang, Lin Liu, Jianping Wang, Yinglan Liu, Shanshan Deng, Tao Jiang

Published in: Cardiovascular Toxicology | Issue 6/2024

Abstract

Vascular lesions frequently arise as complication in patients diagnosed with diabetes mellitus (DM). Presently, percutaneous coronary intervention (PCI) and antithrombotic therapy serve as primary treatments. However, in-stent restenosis persists as a challenging clinical issue following PCI, lacking sustained and effective treatment. Linarin (LN) exhibits diverse pharmacological activities and is regarded as a potential drug for treating various diseases, including DM. But its specific role in restenosis after vascular injury in DM patients remains unclear. A rat model of diabetes-related restenosis was established to evaluate the role of LN on neointimal hyperplasia. Vascular smooth muscle cells (VSMCs) stimulated by high glucose (HG, 30 mM) underwent LN treatment. Additionally, an overexpression plasmid of A disintegrin and metalloproteinases (ADAM10) was constructed to transfect VSMCs. We employed CCK-8, Brdu, wound-healing scratch, and transwell migration assays to evaluate the proliferation and migration of VSMCs. Furthermore, western blot and immunofluorescence assays were utilized to investigate the expressions of ADAM10 and the downstream Notch signaling pathway in vivo and in vitro models. LN notably alleviated intimal hyperplasia after vascular injury in DM rats and reduced the protein expression of ADAM10, alongside its downstream Notch1 signaling pathway-related proteins (Notch1, NICD and Hes1) in rat carotid artery tissues. LN effectively suppressed the proliferation and migration of VSMCs induced by HG, downregulating the protein expression of ADAM10, Notch1, NICD and Hes1. Moreover, our findings indicated that ADAM10 overexpression significantly reversed LN’s effects on proliferation, migration, and the expression of Notch1 signaling pathway-related proteins in HG-treated VSMCs. LN demonstrates potential therapeutic efficacy in addressing restenosis after diabetic-related vascular injury, with the ADAM10 mediated Notch signaling pathway playing a pivotal role.

Li, Y., Liu, Y., Liu, S., Gao, M., Wang, W., Chen, K., Huang, L., & Liu, Y. (2023). Diabetic vascular diseases: Molecular mechanisms and therapeutic strategies. Signal Transduction and Targeted Therapy, 8, 152.CrossRefPubMedPubMedCentral

Avogaro, A., & Fadini, G. P. (2019). Microvascular complications in diabetes: A growing concern for cardiologists. International Journal of Cardiology, 291, 29–35.CrossRefPubMed

Catrina, S. B., & Zheng, X. (2021). Hypoxia and hypoxia-inducible factors in diabetes and its complications. Diabetologia, 64, 709–716.CrossRefPubMedPubMedCentral

Giustino, G., Colombo, A., Camaj, A., Yasumura, K., Mehran, R., Stone, G. W., Kini, A., & Sharma, S. K. (2022). Coronary in-stent restenosis: JACC state-of-the-art review. Journal of the American College of Cardiology, 80, 348–372.CrossRefPubMed

Pepe, M., Napoli, G., Carulli, E., Moscarelli, M., Forleo, C., Nestola, P. L., Biondi-Zoccai, G., Giordano, A., & Favale, S. (2021). Autoimmune diseases in patients undergoing percutaneous coronary intervention: A risk factor for in-stent restenosis? Atherosclerosis, 333, 24–31.CrossRefPubMed

Chevalier, B., Moulichon, R., Teiger, E., Brunel, P., Metzger, J. P., Pansieri, M., Carrie, D., Stoll, H. P., Wittebols, K., Spaulding, C., & Fajadet, J. (2012). One-year results of the CRISTAL Trial, a randomized comparison of cypher sirolimus-eluting coronary stents versus balloon angioplasty for restenosis of drug-eluting stents. Journal of Interventional Cardiology, 25, 586–595.CrossRefPubMed

Pan, H., Zhang, Q., Cui, K., Chen, G., Liu, X., & Wang, L. (2017). Optimization of extraction of linarin from Flos chrysanthemi indici by response surface methodology and artificial neural network. Journal of Separation Science, 40, 2062–2070.CrossRefPubMed

Mottaghipisheh, J., Taghrir, H., Boveiri Dehsheikh, A., Zomorodian, K., Irajie, C., Mahmoodi Sourestani, M., & Iraji, A. (2021). Linarin, a glycosylated flavonoid, with potential therapeutic attributes: A comprehensive review. Pharmaceuticals (Basel), 14(11), 1104. https://doi.org/10.3390/ph14111104CrossRefPubMed

Xie, G., Yang, J., Wei, X., Xu, Q., & Qin, M. (2020). Separation of acteoside and linarin from Buddlejae flos by high-speed countercurrent chromatography and their anti-inflammatory activities. Journal of Separation Science, 43, 1450–1457.CrossRefPubMed

10.

Hwang, S. H., Paek, J. H., & Lim, S. S. (2016). Simultaneous ultra performance liquid chromatography determination and antioxidant activity of linarin, luteolin, chlorogenic acid and apigenin in different parts of compositae species. Molecules, 21(11), 1609. https://doi.org/10.3390/molecules21111609CrossRefPubMedPubMedCentral

11.

Yu, Q., Li, X., & Cao, X. (2017). Linarin could protect myocardial tissue from the injury of Ischemia-reperfusion through activating Nrf-2. Biomedicine & Pharmacotherapy, 90, 1–7.CrossRef

12.

Xie, C., Yue, S., Li, X., Li, Z., Li, W., Huang, G., Ma, G., Liu, W., Wang, Y., & Zhang, Y. (2022). A linarin derivative protects against ischemia-induced neuronal injury in mice by promoting cerebral blood flow recovery via KDELR-dependent CSPG4 activation. Oxidative Medicine and Cellular Longevity, 2022, 6434086.CrossRefPubMedPubMedCentral

13.

Wang, Z., Bai, Z., Yan, J., Liu, T., Li, Y., Xu, J., Meng, X., & Bi, Y. (2022). Anti-diabetic effects of linarin from Chrysanthemi indici Flos via AMPK activation. Chinese Herbal Medicines, 14, 97–103.CrossRefPubMed

14.

Kim, S. J., Cho, H. I., Kim, S. J., Park, J. H., Kim, J. S., Kim, Y. H., Lee, S. K., Kwak, J. H., & Lee, S. M. (2014). Protective effect of linarin against D-galactosamine and lipopolysaccharide-induced fulminant hepatic failure. European Journal of Pharmacology, 738, 66–73.CrossRefPubMed

15.

Zhen, Z. G., Ren, S. H., Ji, H. M., Ma, J. H., Ding, X. M., Feng, F. Q., Chen, S. L., Zou, P., Ren, J. R., & Jia, L. (2017). Linarin suppresses glioma through inhibition of NF-kappaB/p65 and up-regulating p53 expression in vitro and in vivo. Biomedicine & Pharmacotherapy, 95, 363–374.CrossRef

16.

Wang, T., Shan, M. Y., Tang, C. Y., Cheng, M. Y., Chen, B., Yan, J., & Xu, Z. H. (2023). Linarin Ameliorates Diabetic Liver Injury by Alleviating Oxidative Stress and Inflammation through the Inhibition of AKR1B1. Combinatorial Chemistry & High Throughput Screening. https://doi.org/10.2174/1386207326666230412084201CrossRef

17.

Elsworthy, R. J., Hill, E. J., Dunleavy, C., & Aldred, S. (2022). The role of ADAM10 in astrocytes: Implications for Alzheimer’s disease. Frontiers in Aging Neuroscience, 14, 1056507.CrossRefPubMedPubMedCentral

18.

Smith, T. M., Jr., Tharakan, A., & Martin, R. K. (2020). Targeting ADAM10 in cancer and autoimmunity. Frontiers in Immunology, 11, 499.CrossRefPubMedPubMedCentral

19.

Maas, S. L., Donners, M., & van der Vorst, E. P. C. (2023). ADAM10 and ADAM17, major regulators of chronic kidney disease induced atherosclerosis? International Journal of Molecular Sciences, 24(8), 7309.CrossRefPubMedPubMedCentral

20.

Lam, S., Shiu, S. W., Wong, Y., & Tan, K. C. (2022). Effect of type 2 diabetes on A disintegrin and metalloprotease 10. Journal of Diabetes, 14, 394–400.CrossRefPubMedPubMedCentral

21.

Shao, M., Yu, M., Zhao, J., Mei, J., Pan, Y., Zhang, J., Wu, H., Yu, M., Liu, F., & Chen, G. (2020). miR-21-3p regulates AGE/RAGE signalling and improves diabetic atherosclerosis. Cell Biochemistry and Function, 38, 965–975.CrossRefPubMed

22.

Yang, K., Lu, L., Liu, Y., Zhang, Q., Pu, L. J., Wang, L. J., Zhu, Z. B., Wang, Y. N., Meng, H., Zhang, X. J., Du, R., Chen, Q. J., & Shen, W. F. (2013). Increase of ADAM10 level in coronary artery in-stent restenosis segments in diabetic minipigs: High ADAM10 expression promoting growth and migration in human vascular smooth muscle cells via Notch 1 and 3. PLoS ONE, 8, e83853.CrossRefPubMedPubMedCentral

23.

Feng, L., Wang, J., & Ma, X. (2018). Exogenous SERP1 attenuates restenosis by restoring GLP-1 receptor activity in diabetic rats following vascular injury. Biomedicine & Pharmacotherapy, 103, 290–300.CrossRef

24.

Wang, X., Li, T., Ma, B., Zhao, Z., Ni, L., Zhang, R., Niu, S., & Liu, C. (2021). Melatonin attenuates restenosis after vascular injury in diabetic rats through activation of the Nrf2 signaling pathway. Biochemical and Biophysical Research Communications, 548, 127–133.CrossRefPubMed

25.

Pavic, G., Grandoch, M., Dangwal, S., Jobi, K., Rauch, B. H., Doller, A., Oberhuber, A., Akhyari, P., Schrör, K., Fischer, J. W., & Fender, A. C. (2014). Thrombin receptor protease-activated receptor 4 is a key regulator of exaggerated intimal thickening in diabetes mellitus. Circulation, 130, 1700–1711.CrossRefPubMed

26.

Li, B., Zhu, C., Dong, L., Qin, J., Xiang, W., Davidson, A. J., Feng, S., Wang, Y., Shen, X., Weng, C., Wang, C., Zhu, T., Teng, L., Wang, J., Englert, C., Chen, J., & Jiang, H. (2020). ADAM10 mediates ectopic proximal tubule development and renal fibrosis through Notch signalling. The Journal of Pathology, 252, 274–289.CrossRefPubMed

27.

Meng, H., Li, B., Xu, W., Ding, R., Xu, S., Wu, Q., & Zhang, Y. (2022). miR-140-3p enhances the sensitivity of LUAD cells to antitumor agents by targeting the ADAM10/Notch pathway. Journal of Cancer, 13, 3660–3673.CrossRefPubMedPubMedCentral

28.

Alabi, R. O., Lora, J., Celen, A. B., Maretzky, T., & Blobel, C. P. (2021). Analysis of the conditions that affect the selective processing of endogenous Notch1 by ADAM10 and ADAM17. International Journal of Molecular Sciences, 22(4), 1846. https://doi.org/10.3390/ijms22041846CrossRefPubMedPubMedCentral

29.

van Tetering, G., van Diest, P., Verlaan, I., van der Wall, E., Kopan, R., & Vooijs, M. (2009). Metalloprotease ADAM10 is required for Notch1 site 2 cleavage. Journal of Biological Chemistry, 284, 31018–31027.CrossRefPubMedPubMedCentral

30.

Alabi, R. O., Glomski, K., Haxaire, C., Weskamp, G., Monette, S., & Blobel, C. P. (2016). ADAM10-dependent signaling through Notch1 and Notch4 controls development of organ-specific vascular beds. Circulation Research, 119, 519–531.CrossRefPubMedPubMedCentral

31.

Seo, H. H., Kim, S. W., Lee, C. Y., Lim, K. H., Lee, J., Lim, S., Lee, S., & Hwang, K. C. (2017). 7-cyclopentyl-5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d] pyrimidin-4-ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways. European Journal of Pharmacology, 798, 35–42.CrossRefPubMed

32.

Liu, H., Dong, W., Lin, Z., Lu, J., Wan, H., Zhou, Z., & Liu, Z. (2013). CCN4 regulates vascular smooth muscle cell migration and proliferation. Molecules and Cells, 36, 112–118.CrossRefPubMedPubMedCentral

33.

Xu, Y., Lai, Y., Cao, L., Li, Y., Chen, G., Chen, L., Weng, H., Chen, T., Wang, L., & Ye, Y. (2021). Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-451a represses epithelial-mesenchymal transition of hepatocellular carcinoma cells by inhibiting ADAM10. RNA Biology, 18, 1408–1423.CrossRefPubMed

34.

Cheng, Y., Lin, L., Li, X., Lu, A., Hou, C., Wu, Q., Hu, X., Zhou, Z., Chen, Z., & Tang, F. (2021). ADAM10 is involved in the oncogenic process and chemo-resistance of triple-negative breast cancer via regulating Notch1 signaling pathway, CD44 and PrPc. Cancer Cell International, 21, 32.CrossRefPubMedPubMedCentral

35.

Guo, D., Huang, F., Xue, R., Ma, Y., Xiao, L., Lou, H., & Pan, S. (2023). A disintegrin and metalloproteinase 10 (ADAM10) is essential for oligodendrocyte precursor development and myelination in the mouse brain. Molecular Neurobiology, 60, 1675–1689.CrossRefPubMed

Title: Linarin Ameliorates Restenosis After Vascular Injury in Type 2 Diabetes Mellitus via Regulating ADAM10-Mediated Notch Signaling Pathway
Authors: Aihua Jiang
Lin Liu
Jianping Wang
Yinglan Liu
Shanshan Deng
Tao Jiang
Publication date: 01-05-2024
Publisher: Springer US
Keyword: Diabetes
Published in: Cardiovascular Toxicology / Issue 6/2024
Print ISSN: 1530-7905
Electronic ISSN: 1559-0259
DOI: https://doi.org/10.1007/s12012-024-09863-4

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Linarin Ameliorates Restenosis After Vascular Injury in Type 2 Diabetes Mellitus via Regulating ADAM10-Mediated Notch Signaling Pathway

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2024

Assessment of Native Myocardial T1 Mapping for Early Detection of Anthracycline-Induced Cardiotoxicity in Patients with Cancer: a Systematic Review and Meta-analysis

Role of Early Left Atrial Functional Decline in Predicting Cardiotoxicity in HER2 Positive Breast Cancer Patients Treated With Trastuzumab

USP18 Curbs the Progression of Metabolic Hypertension by Suppressing JAK/STAT Pathway

Correction: Uncovering the Mechanism of Chinese Hawthorn Leaf on Myocardial Ischemia Based on Network Pharmacology, Molecular Docking Verification, and In Vitro Studies

SIRT6 in Regulation of Mitochondrial Damage and Associated Cardiac Dysfunctions: A Possible Therapeutic Target for CVDs

Effect of Stanozolol and/or Cannabis Abuse on Hypertrophic Mechanism and Oxidative Stress of Male Albino Rat Cardiac Tissue in Relation to Exercise: A Sport Abuse Practice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page